 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «123456789101112» |
- | alendronate / Generic mfg.
Enrollment open, Trial completion date, Trial primary completion date: 64 Cu-DOTA-alendronate PET Imaging in Localizing and Characterizing Breast Calcifications in Participants Before Undergoing Mastectomy (clinicaltrials.gov) - Aug 11, 2021
P1, N=6, Recruiting, Sponsor: City of Hope Medical Center
Suspended --> Recruiting | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
- | alendronate / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: Safety and Tolerability of Intravenous LLP2A-Alendronate for Osteopenia Secondary to Glucocorticoids (clinicaltrials.gov) - Aug 6, 2021
P1, N=58, Completed, Sponsor: Nancy E. Lane, MD
Suspended --> Recruiting | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023 Active, not recruiting --> Completed | Trial completion date: Jun 2021 --> Mar 2021 | Trial primary completion date: Jun 2021 --> Mar 2021
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion, Enrollment change: Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study (clinicaltrials.gov) - Jul 26, 2021
P1, N=30, Completed, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed | Trial completion date: Jun 2021 --> Mar 2021 | Trial primary completion date: Jun 2021 --> Mar 2021 Active, not recruiting --> Completed | N=75 --> 30
- | alendronate / Generic mfg., cinacalcet HCl / Generic mfg.
Trial completion date, Trial primary completion date: Renal Osteodystrophy: An Individual Management Approach (clinicaltrials.gov) - Jul 14, 2021
P=N/A, N=120, Active, not recruiting, Sponsor: Hartmut Malluche, MD
Active, not recruiting --> Completed | N=75 --> 30 Trial completion date: Jun 2021 --> Jun 2023 | Trial primary completion date: Jun 2021 --> Jun 2023
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion date, Trial primary completion date: BAD: Alendronate in an Weekly Effervescent Tablet Formulation Following Denosumab Discontinuation (clinicaltrials.gov) - Jul 14, 2021
P=N/A, N=100, Recruiting, Sponsor: 251 Hellenic Air Force & VA General Hospital
Trial completion date: Jun 2021 --> Jun 2023 | Trial primary completion date: Jun 2021 --> Jun 2023 Trial completion date: Apr 2022 --> Apr 2023 | Trial primary completion date: Oct 2021 --> Oct 2022
- ||||| alendronate / Generic mfg.
New P4 trial: IMMINENT study_Osteoporosis Estudio IMMINENT_Osteoporosis (EUDRACT) - Jul 10, 2021
P4, N=376, Ongoing, Sponsor: Gedeon Richter Ibérica
- | alendronate / Generic mfg.
Trial primary completion date: Safety and Tolerability of Intravenous LLP2A-Alendronate for Osteopenia Secondary to Glucocorticoids (clinicaltrials.gov) - Jun 16, 2021
P1, N=59, Active, not recruiting, Sponsor: Nancy E. Lane, MD
Trial completion date: Apr 2022 --> Apr 2023 | Trial primary completion date: Oct 2021 --> Oct 2022 Trial primary completion date: Mar 2021 --> Jun 2021
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion date, Trial primary completion date: Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study (clinicaltrials.gov) - May 13, 2021
P1, N=75, Active, not recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Mar 2021 --> Jun 2021 Trial completion date: Oct 2021 --> Jul 2021 | Trial primary completion date: Oct 2020 --> Jul 2021
- || Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Trial initiation date: Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa (clinicaltrials.gov) - May 12, 2021
P1, N=75, Not yet recruiting, Sponsor: Karen Klahr Miller, MD
Trial completion date: Oct 2021 --> Jul 2021 | Trial primary completion date: Oct 2020 --> Jul 2021 Initiation date: Apr 2021 --> Aug 2021
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
New trial: Osteoporosis Treatment Protocol in Patients With Fragility Fractures: Application and Efficacy (clinicaltrials.gov) - Apr 27, 2021
P, N=350, Recruiting, Sponsor: University General Hospital of Heraklion
- || Evenity (romosozumab) / Astellas, Amgen, UCB
Enrollment open: Romosozumab in Women With Chronic SCI (clinicaltrials.gov) - Mar 5, 2021
P2, N=12, Recruiting, Sponsor: Northwestern University
Initiation date: Apr 2021 --> Aug 2021 Not yet recruiting --> Recruiting
- ||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
New P1 trial: Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa (clinicaltrials.gov) - Mar 2, 2021
P1, N=75, Not yet recruiting, Sponsor: Karen Klahr Miller, MD
- | alendronate / Generic mfg.
Trial suspension: 64 Cu-DOTA-alendronate PET Imaging in Localizing and Characterizing Breast Calcifications in Participants Before Undergoing Mastectomy (clinicaltrials.gov) - Feb 10, 2021
P1, N=6, Suspended, Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting Recruiting --> Suspended
- | alendronate / Generic mfg.
Trial initiation date: RadBone: Bone Toxicity Following Pelvic Radiotherapy (clinicaltrials.gov) - Feb 7, 2021
P=N/A, N=80, Not yet recruiting, Sponsor: The Christie NHS Foundation Trust
Recruiting --> Suspended Initiation date: Nov 2020 --> Apr 2021
- |||| alendronate / Generic mfg.
New P4 trial: A Study of Alendronate Sodium Vitamin D3 Tablets on Knee Osteoarthritis (clinicaltrials.gov) - Feb 4, 2021
P4, N=60, Not yet recruiting, Sponsor: Peking Union Medical College Hospital
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion date: Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study (clinicaltrials.gov) - Jan 22, 2021
P1, N=75, Active, not recruiting, Sponsor: Massachusetts General Hospital
Initiation date: Nov 2020 --> Apr 2021 Trial completion date: Sep 2020 --> Oct 2021
- || Evenity (romosozumab) / Astellas, Amgen, UCB
New P2 trial: Romosozumab in Women With Chronic SCI (clinicaltrials.gov) - Jan 14, 2021
P2, N=12, Not yet recruiting, Sponsor: Northwestern University
- | alendronate / Generic mfg., propranolol / Generic mfg.
New P3 trial: Clinical Study Evaluating Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis (clinicaltrials.gov) - Jan 12, 2021
P3, N=50, Recruiting, Sponsor: Sherief Abd-Elsalam
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment open: Denosumab (DMAB) Discontinuation And Switching In Glucocorticoid-Induced Osteoporosis (GIOP): A Pilot Study (clinicaltrials.gov) - Jan 11, 2021
P4, N=45, Recruiting, Sponsor: University of Alabama at Birmingham
Trial completion date: Sep 2020 --> Oct 2021 Not yet recruiting --> Recruiting
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment closed, Enrollment change: Alendronate Versus Denosumab in Kidney Transplant Patients (clinicaltrials.gov) - Dec 11, 2020
P2/3, N=90, Active, not recruiting, Sponsor: Ain Shams University
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=60 --> 90
- ||| alendronate / Generic mfg.
Enrollment open, Trial completion date, Trial primary completion date, Patient reported outcomes: Effect of Alendronate 70mg Formulation on Bone Turnover Markers and Patient Reported Outcomes (clinicaltrials.gov) - Dec 3, 2020
P=N/A, N=80, Recruiting, Sponsor: Labatec Pharma SA
Recruiting --> Active, not recruiting | N=60 --> 90 Not yet recruiting --> Recruiting | Trial completion date: Aug 2019 --> Dec 2022 | Trial primary completion date: Aug 2019 --> Mar 2022
- | alendronate / Generic mfg.
Trial primary completion date: Safety and Tolerability of Intravenous LLP2A-Alendronate for Osteopenia Secondary to Glucocorticoids (clinicaltrials.gov) - Nov 17, 2020
P1, N=59, Active, not recruiting, Sponsor: Nancy E. Lane, MD
Not yet recruiting --> Recruiting | Trial completion date: Aug 2019 --> Dec 2022 | Trial primary completion date: Aug 2019 --> Mar 2022 Trial primary completion date: Oct 2020 --> Mar 2021
- | alendronate / Generic mfg.
Enrollment change, Trial termination: Pilot Study of Bisphosphonates for Breast Cancer (clinicaltrials.gov) - Oct 22, 2020
P1, N=6, Terminated, Sponsor: University of Wisconsin, Madison
Trial primary completion date: Oct 2020 --> Mar 2021 N=20 --> 6 | Suspended --> Terminated
- | alendronate / Generic mfg.
Enrollment open, Trial completion date, Trial primary completion date: 64 Cu-DOTA-alendronate PET Imaging in Localizing and Characterizing Breast Calcifications in Participants Before Undergoing Mastectomy (clinicaltrials.gov) - Sep 23, 2020
P1, N=6, Recruiting, Sponsor: City of Hope Medical Center
N=20 --> 6 | Suspended --> Terminated Not yet recruiting --> Recruiting | Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: Dec 2020 --> Dec 2022
- | alendronate / Generic mfg.
New trial: RadBone: Bone Toxicity Following Pelvic Radiotherapy (clinicaltrials.gov) - Sep 17, 2020
P=N/A, N=80, Not yet recruiting, Sponsor: The Christie NHS Foundation Trust
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment change, Trial completion date, Trial primary completion date: Comparative Antiresorptive Efficacy Discontinuation of Denosumab (clinicaltrials.gov) - Sep 11, 2020
P4, N=71, Recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting | Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: Dec 2020 --> Dec 2022 N=50 --> 71 | Trial completion date: Dec 2021 --> Jan 2025 | Trial primary completion date: Sep 2021 --> Aug 2024
- | alendronate / Generic mfg.
Trial termination: Stem Cell Recruitment in Osteoporosis Therapy (clinicaltrials.gov) - Aug 21, 2020
P=N/A, N=55, Terminated, Sponsor: Johns Hopkins University
N=50 --> 71 | Trial completion date: Dec 2021 --> Jan 2025 | Trial primary completion date: Sep 2021 --> Aug 2024 Active, not recruiting --> Terminated; Inability to analyze collected samples due to no funds.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial initiation date: Denosumab (DMAB) Discontinuation And Switching In Glucocorticoid-Induced Osteoporosis (GIOP): A Pilot Study (clinicaltrials.gov) - Aug 12, 2020
P4, N=45, Not yet recruiting, Sponsor: University of Alabama at Birmingham
Active, not recruiting --> Terminated; Inability to analyze collected samples due to no funds. Initiation date: Jun 2020 --> Oct 2020
- | alendronate / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: 99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis (clinicaltrials.gov) - Aug 9, 2020
P=N/A, N=206, Completed, Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Initiation date: Jun 2020 --> Oct 2020 Recruiting --> Completed | Trial completion date: Jun 2020 --> Dec 2019 | Trial primary completion date: Jun 2020 --> Dec 2019
- | alendronate / Generic mfg., cinacalcet HCl / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: Renal Osteodystrophy: An Individual Management Approach (clinicaltrials.gov) - Jul 13, 2020
P=N/A, N=120, Active, not recruiting, Sponsor: Hartmut Malluche, MD
Recruiting --> Completed | Trial completion date: Jun 2020 --> Dec 2019 | Trial primary completion date: Jun 2020 --> Dec 2019 Recruiting --> Active, not recruiting | Trial completion date: Jun 2020 --> Jun 2021 | Trial primary completion date: Jun 2020 --> Jun 2021
- | alendronate / Generic mfg.
Enrollment closed, Enrollment change, Trial completion date: ALOSTRA: Alendronate Treatment of Osteoporosis in Rheumatoid Arthritis (clinicaltrials.gov) - Jul 7, 2020
P2, N=69, Active, not recruiting, Sponsor: University of Aarhus
Recruiting --> Active, not recruiting | Trial completion date: Jun 2020 --> Jun 2021 | Trial primary completion date: Jun 2020 --> Jun 2021 Recruiting --> Active, not recruiting | N=160 --> 69 | Trial completion date: Jul 2021 --> Dec 2021
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion date, Trial primary completion date: Denosumab Safety Assessment in Multiple Observational Databases (clinicaltrials.gov) - Jun 17, 2020
P=N/A, N=508215, Active, not recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting | N=160 --> 69 | Trial completion date: Jul 2021 --> Dec 2021 Trial completion date: May 2020 --> Aug 2024 | Trial primary completion date: May 2020 --> Mar 2024
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
New P2 trial: The Use of Steovess/Binosto After Denosumab Discontinuation to Prevent Increase in Bone Turnover (clinicaltrials.gov) - May 27, 2020
P2, N=40, Recruiting, Sponsor: University Hospital, Ghent
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial initiation date: Denosumab (DMAB) Discontinuation And Switching In Glucocorticoid-Induced Osteoporosis (GIOP): A Pilot Study (clinicaltrials.gov) - Apr 27, 2020
P4, N=45, Not yet recruiting, Sponsor: University of Alabama at Birmingham
Trial completion date: May 2020 --> Aug 2024 | Trial primary completion date: May 2020 --> Mar 2024 Initiation date: Feb 2020 --> Jun 2020
- | alendronate / Generic mfg.
Trial completion date, Trial primary completion date: Pilot Study of Bisphosphonates for Breast Cancer (clinicaltrials.gov) - Apr 9, 2020
P1, N=20, Suspended, Sponsor: University of Wisconsin, Madison
Initiation date: Feb 2020 --> Jun 2020 Trial completion date: Mar 2020 --> Mar 2021 | Trial primary completion date: Mar 2020 --> Mar 2021
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
New trial: BAD: Alendronate in an Weekly Effervescent Tablet Formulation Following Denosumab Discontinuation (clinicaltrials.gov) - Apr 7, 2020
P, N=100, Recruiting, Sponsor: 251 Hellenic Air Force & VA General Hospital
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment closed: Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study (clinicaltrials.gov) - Mar 13, 2020
P1, N=75, Active, not recruiting, Sponsor: Massachusetts General Hospital
Trial completion date: Mar 2020 --> Mar 2021 | Trial primary completion date: Mar 2020 --> Mar 2021 Recruiting --> Active, not recruiting
- | alendronate / Generic mfg.
Trial completion date, Trial primary completion date: Safety and Tolerability of Intravenous LLP2A-Alendronate for Osteopenia Secondary to Glucocorticoids (clinicaltrials.gov) - Feb 27, 2020
P1, N=50, Active, not recruiting, Sponsor: Nancy E. Lane, MD
Recruiting --> Active, not recruiting Trial completion date: Jun 2020 --> Jun 2021 | Trial primary completion date: Jan 2020 --> Oct 2020
- | alendronate / Generic mfg.
Trial suspension: Pilot Study of Bisphosphonates for Breast Cancer (clinicaltrials.gov) - Feb 19, 2020
P1, N=20, Suspended, Sponsor: University of Wisconsin, Madison
Trial completion date: Jun 2020 --> Jun 2021 | Trial primary completion date: Jan 2020 --> Oct 2020 Recruiting --> Suspended
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion, Enrollment change: Denosumab Versus Bisphosphonates (Alendronate) in GIOP (clinicaltrials.gov) - Feb 12, 2020
P4, N=140, Completed, Sponsor: Tuen Mun Hospital
Recruiting --> Suspended Active, not recruiting --> Completed | N=220 --> 140
- | alendronate / Generic mfg.
Trial completion date: Pilot Study of Bisphosphonates for Breast Cancer (clinicaltrials.gov) - Jan 18, 2020
P1, N=20, Recruiting, Sponsor: University of Wisconsin, Madison
Active, not recruiting --> Completed | N=220 --> 140 Trial completion date: Aug 2020 --> Mar 2020
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion date, Trial primary completion date: Denosumab Safety Assessment in Multiple Observational Databases (clinicaltrials.gov) - Jan 2, 2020
P=N/A, N=508215, Active, not recruiting, Sponsor: Amgen
Trial completion date: Aug 2020 --> Mar 2020 Trial completion date: Jun 2023 --> May 2020 | Trial primary completion date: Jun 2023 --> May 2020
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
New P4 trial: Denosumab (DMAB) Discontinuation And Switching In Glucocorticoid-Induced Osteoporosis (GIOP): A Pilot Study (clinicaltrials.gov) - Nov 25, 2019
P4, N=45, Not yet recruiting, Sponsor: University of Alabama at Birmingham
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
New P2/3 trial: Alendronate Versus Denosumab in Kidney Transplant Patients (clinicaltrials.gov) - Nov 20, 2019
P2/3, N=60, Recruiting, Sponsor: Ain Shams University
- | alendronate / Generic mfg.
New P1/2 trial: Efficacy of Antiresorptive and Bone Forming Material on Dental Implants (clinicaltrials.gov) - Nov 15, 2019
P1/2, N=20, Enrolling by invitation, Sponsor: University of Baghdad
- | alendronate / Generic mfg.
Trial completion date, Trial primary completion date: APART: Alendronate for Prevention of AntiRetroviral Therapy-associated Bone Loss (clinicaltrials.gov) - Sep 25, 2019
P4, N=80, Recruiting, Sponsor: University College Dublin
Trial completion date: Jun 2023 --> May 2020 | Trial primary completion date: Jun 2023 --> May 2020 Trial completion date: Oct 2018 --> Mar 2021 | Trial primary completion date: Oct 2017 --> Dec 2020
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Trial completion date, Trial primary completion date: Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study (clinicaltrials.gov) - Sep 6, 2019
P1, N=75, Recruiting, Sponsor: Massachusetts General Hospital
Trial completion date: Oct 2018 --> Mar 2021 | Trial primary completion date: Oct 2017 --> Dec 2020 Trial completion date: May 2020 --> Sep 2020 | Trial primary completion date: May 2020 --> Sep 2020
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment closed: Denosumab Versus Bisphosphonates (Alendronate) in GIOP (clinicaltrials.gov) - Sep 4, 2019
P4, N=220, Active, not recruiting, Sponsor: Tuen Mun Hospital
Trial completion date: May 2020 --> Sep 2020 | Trial primary completion date: May 2020 --> Sep 2020 Recruiting --> Active, not recruiting
- | alendronate / Generic mfg.
Trial completion date, Trial primary completion date: 99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis (clinicaltrials.gov) - Jul 8, 2019
P=N/A, N=206, Recruiting, Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Recruiting --> Active, not recruiting Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Jun 2019 --> Jun 2020
- | alendronate / Generic mfg.
Enrollment closed: Safety and Tolerability of Intravenous LLP2A-Alendronate for Osteopenia Secondary to Glucocorticoids (clinicaltrials.gov) - Jun 14, 2019
P1, N=50, Active, not recruiting, Sponsor: Nancy E. Lane, MD
Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Jun 2019 --> Jun 2020 Recruiting --> Active, not recruiting